Loading provider…
Loading provider…
Hematology (Internal Medicine) Physician in Duarte, CA
NPI: 1427493998Primary Employer
City of Hope Medical - San Bernardino Radiation Oncology
cityofhope.org
HQ Phone
Get MD John's Phone Numberphone_androidMobile
Get MD John's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2016 - 2026
PA State Medical License
2013 - 2016

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Stanford Health Care
Fellowship • Blood & Bone Marrow Transplant
2020 - 2021
Post-Doctoral Fellowship • 2019 - 2020
2019 - 2020
Fellowship • Hematology and Medical Oncology
2016 - 2019
University of Pennsylvania Health System
Residency • Internal Medicine
2014 - 2016
Internship • Internal Medicine
2013 - 2014
University of Arkansas For Medical Sciences College of Medicine
Medical School
Until 2013
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 80 | 182 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 79 | 463 |
| 3 | 99497Advance care planning by the physician or other qualified health care professional | 14 | 14 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 13 | 13 |
A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist.
Authors: Ong, Shin Yeu, Baird, John H
Journal: J Intensive Care Med
Publication Date: 2023-10-29
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy.
Authors: Andrew Johnsrud
Publication Date: 2021-03-15
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Bone Marrow Biopsy, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, DRUG: Acalabrutinib, PROCEDURE: Computed Tomography, PROCEDURE: Multigated Acquisition Scan, PROCEDURE: Echocardiography, BIOLOGICAL: Obinutuzumab, BIOLOGICAL: Glofitamab
Lead Sponsor: CARGO Therapeutics
Intervention / Treatment: DRUG: firi-cel (Experimental drug), DRUG: Fludarabine (Conditional therapy), DRUG: Cyclophosphamide Monohydrate (Conditional therapy)
Lead Sponsor: Janssen Research & Development, LLC
Intervention / Treatment: BIOLOGICAL: JNJ-90014496